Organization
Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center
6 abstracts
Abstract
MRI-Linac radiation therapy outcomes in patients with prostate, breast and other advanced malignancies.Org: Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Radiation Oncology Division,
Abstract
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).Org: Institut Gustave Roussy, The Royal Marsden Hospital (Surrey), London, United Kingdom, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Hospitals Seidman Cancer Center, START San Antonio,
Abstract
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.Org: Mary Crowley Cancer Research Center, Dallas, Next Oncology Virginia and Virginia Cancer Specialists, San Antonio Breast Cancer Symposium, Northwell Health Cancer Institute,
Abstract
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.Org: Institut Curie, Saint Cloud, France, Virginia Cancer Specialists, Columbia University Medical Center, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Providence Cancer Institute,
Abstract
Improved outcomes from reflex comprehensive genomic profiling-guided precision therapeutic selection across a major US healthcare system.Org: Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Illumina, Inc., Health Research Accelerator, Providence Health/St John Cancer Institute,